DE69729796D1 - USE OF SYNERGISTIC COMPOSITIONS OF IL-12 AND IFN-ALPHA FOR THE TREATMENT OF INFECTIOUS DISEASES - Google Patents

USE OF SYNERGISTIC COMPOSITIONS OF IL-12 AND IFN-ALPHA FOR THE TREATMENT OF INFECTIOUS DISEASES

Info

Publication number
DE69729796D1
DE69729796D1 DE69729796T DE69729796T DE69729796D1 DE 69729796 D1 DE69729796 D1 DE 69729796D1 DE 69729796 T DE69729796 T DE 69729796T DE 69729796 T DE69729796 T DE 69729796T DE 69729796 D1 DE69729796 D1 DE 69729796D1
Authority
DE
Germany
Prior art keywords
ifn
alpha
treatment
infectious diseases
synergistic compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69729796T
Other languages
German (de)
Other versions
DE69729796T2 (en
Inventor
Gottfried Alber
Anne Carr
Albert Mattner
John Mulqueen
Kathrin Palmer
Andre Rogerson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE69729796D1 publication Critical patent/DE69729796D1/en
Application granted granted Critical
Publication of DE69729796T2 publication Critical patent/DE69729796T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69729796T 1996-05-13 1997-05-07 USE OF SYNERGISTIC COMPOSITIONS OF IL-12 AND IFN-ALPHA FOR THE TREATMENT OF INFECTIOUS DISEASES Expired - Fee Related DE69729796T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9609932 1996-05-13
GBGB9609932.0A GB9609932D0 (en) 1996-05-13 1996-05-13 Use of IL-12 and IFN alpha for the treatment of infectious diseases
PCT/EP1997/002336 WO1997042969A1 (en) 1996-05-13 1997-05-07 USE OF IL-12 AND IFN-α FOR THE TREATMENT OF INFECTIOUS DISEASES

Publications (2)

Publication Number Publication Date
DE69729796D1 true DE69729796D1 (en) 2004-08-12
DE69729796T2 DE69729796T2 (en) 2005-07-14

Family

ID=10793602

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69729796T Expired - Fee Related DE69729796T2 (en) 1996-05-13 1997-05-07 USE OF SYNERGISTIC COMPOSITIONS OF IL-12 AND IFN-ALPHA FOR THE TREATMENT OF INFECTIOUS DISEASES

Country Status (14)

Country Link
US (1) US5928636A (en)
EP (1) EP0907373B1 (en)
JP (1) JP3246918B2 (en)
CN (1) CN1178694C (en)
AR (1) AR007051A1 (en)
AT (1) ATE270556T1 (en)
BR (1) BR9709238A (en)
CA (1) CA2253490C (en)
DE (1) DE69729796T2 (en)
ES (1) ES2224246T3 (en)
GB (1) GB9609932D0 (en)
PT (1) PT907373E (en)
TR (1) TR199802329T2 (en)
WO (1) WO1997042969A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1108050B1 (en) * 1998-08-26 2004-10-06 Heinz Schaller Methods and compositions for expressing heterologous genes in hepatocytes using hepadnaviral vectors
WO2000051631A2 (en) * 1999-03-02 2000-09-08 Schering Corporation Pegylated alpha interferon for hiv therapy
JP2002543144A (en) * 1999-05-04 2002-12-17 シェーリング コーポレイション HIV therapy combined with PEGylated interferon αCCR5 antagonist
US6635646B1 (en) 1999-05-04 2003-10-21 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
EP1263457A2 (en) * 2000-03-09 2002-12-11 Schering Corporation Hiv immune adjuvant therapy
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1294735A2 (en) 2000-05-26 2003-03-26 Novirio Pharmaceuticals Limited Methods and compositions for treating flaviviruses and pestiviruses
WO2002044717A1 (en) * 2000-12-01 2002-06-06 Cornell Research Foundation Animal model for flaviviridae infection
US7138376B2 (en) * 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN100348607C (en) 2002-06-28 2007-11-14 埃迪尼克斯(开曼)有限公司 For the treatment of Flaviviridae viral infection in 2 'and 3'-nucleoside prodrugs
MXPA04012802A (en) * 2002-06-28 2005-04-19 Idenix Cayman Ltd 2aCOE-C-METHYL-3aCOE-O-L-VALINE ESTER RIBOFURANOSYL CYTIDINE FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS.
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7824851B2 (en) * 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
WO2004052899A2 (en) * 2002-12-12 2004-06-24 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
EP1599171A2 (en) * 2003-02-28 2005-11-30 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
PT1633766T (en) 2003-05-30 2019-06-04 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
WO2005046746A2 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
US20060018875A1 (en) * 2004-06-14 2006-01-26 Blatt Lawrence M Interferon compositions and methods of use thereof
CN101023094B (en) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
WO2006031725A2 (en) * 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
ES2302402B1 (en) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. USE OF A CYTOQUINE OF THE INTERLEUQUINA-6 FAMILY IN THE PREPARATION OF A COMPOSITION FOR ADMINISTRATION COMBINED WITH INTERFERON-ALFA.
US7781576B2 (en) * 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EA022952B1 (en) * 2008-07-23 2016-03-31 Тамара Александровна ВИТКАЛОВА Method for treating viral hepatitis b and c
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
TWI598358B (en) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
UY33311A (en) 2010-03-31 2011-10-31 Pharmasset Inc NUCLEOSID PHOSPHORAMIDATES
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
CN102309758B (en) * 2010-07-02 2013-02-20 北京凯因科技股份有限公司 Medicinal composition for treating diseases caused by enterovirus infections
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN102512448B (en) * 2011-12-30 2013-03-27 江苏省疾病预防控制中心 Application of DC-CIK (Dendritic Cell-Cytokine-Induced Killer) cells in preparation of medicine used for resisting HIV (Human Immunodeficiency Virus) infection
RU2482848C1 (en) * 2011-12-30 2013-05-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения и социального развития Российской Федерации Method of treating patients with drug-resistant tuberculosis or hiv-infection
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
MX2016002185A (en) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Combination formulation of two antiviral compounds.
WO2019016109A1 (en) * 2017-07-17 2019-01-24 Chu De Nantes - Centre Hospitalier Unversitaire De Nantes Interleukin 12 (il12) or derivative thereof for use in the treatment of secondary disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO164037C (en) * 1980-01-08 1990-08-22 Biogen Inc PROCEDURE FOR PREPARING A POLYPEPTIDE OF INTERFERON ALFA (IFNALFA) TYPE.
CH657141A5 (en) * 1980-07-01 1986-08-15 Hoffmann La Roche DNA SEQUENCES, RECOMBINANT EXPRESSION VECTORS FOR THE MICROBIAL PRODUCTION OF HUMAN LEUKOCYTE INTERFERON AND TRANSFORMED MICROORGANISMS.
ATE47864T1 (en) * 1984-08-27 1989-11-15 Genentech Inc MISCELLANEOUS FAMILY OF HUMAN WBC INTERFERONS, COMPOSITIONS CONTAINING THEM, METHODS FOR THEIR PRODUCTION, AND DNA AND TRANSFECTED HOSTS THEREOF.
CA2002607C (en) * 1988-11-10 2004-01-27 Gordon G. Wong Natural killer stimulatory factor
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
DK0790309T3 (en) * 1989-12-22 2007-11-05 Hoffmann La Roche Cytotoxic 40kD subunit of lymphocyte maturation factor and monoclonal antibodies directed thereto
CA2180193A1 (en) * 1995-06-28 1996-12-29 Edward Baral Enhancing host immunity against viral infections

Also Published As

Publication number Publication date
PT907373E (en) 2004-10-29
EP0907373B1 (en) 2004-07-07
CA2253490C (en) 2003-02-04
US5928636A (en) 1999-07-27
BR9709238A (en) 1999-08-10
TR199802329T2 (en) 2002-12-23
CA2253490A1 (en) 1997-11-20
JP3246918B2 (en) 2002-01-15
ES2224246T3 (en) 2005-03-01
DE69729796T2 (en) 2005-07-14
ATE270556T1 (en) 2004-07-15
EP0907373A1 (en) 1999-04-14
AR007051A1 (en) 1999-10-13
JP2000504029A (en) 2000-04-04
CN1178694C (en) 2004-12-08
CN1218410A (en) 1999-06-02
WO1997042969A1 (en) 1997-11-20
GB9609932D0 (en) 1996-07-17

Similar Documents

Publication Publication Date Title
DE69729796D1 (en) USE OF SYNERGISTIC COMPOSITIONS OF IL-12 AND IFN-ALPHA FOR THE TREATMENT OF INFECTIOUS DISEASES
DE69509544D1 (en) COMPOSITION FOR THE TREATMENT OF OVARIAL OSTROGEN-DEPENDENT DISEASES
ATE201138T1 (en) USE OF ANTI-MICROTUBULAR AGENTS FOR THE TREATMENT AND PROPHYLAXIS OF MULTIPLE SCLERosis
DE69836752D1 (en) PROSTAGLAND INAGONIST AND ITS USE FOR THE TREATMENT OF BONE DISEASES
DE69826811D1 (en) Compositions for use in the treatment and prevention of hyperuricaemia
DE69829866D1 (en) SCLEROTIC PROSTHESIS FOR THE TREATMENT OF AGING AND OTHER EYE DISEASES
DE69739758D1 (en) VACCINE FOR THE TREATMENT OF LYMPHOMA AND LEUKEMIA
DE3579113D1 (en) COMPOSITIONS FOR THE REDUCTION, TREATMENT AND DETERMINATION OF ARTHRIC DISEASES AND SIMILAR CONDITIONS.
ATE229815T1 (en) IN VITRO METHODS AND USE OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INNER EAR HAIR CELLS
DE69828620D1 (en) METHOD AND COMPOSITIONS FOR PREVENTING AND TREATING THE CHRONOLOGICAL AGING OF HUMAN SKIN
ATE214274T1 (en) ANTICONVULSIVALS FOR USE IN THE TREATMENT OF AMYOTROPIC LATERAL SCLERosis
DE60023128D1 (en) PYRAZOLECARBOXAMIDE FOR THE TREATMENT OF FATIBILITY AND OTHER DISEASES
DE59608738D1 (en) USE OF EPINASTIN FOR THE TREATMENT OF PAIN
ATE262895T1 (en) USE OF MAILLARD REACTION INHIBITORS FOR THE TREATMENT OF DISEASES CAUSED BY AMYLOIDOSIS
ATA11989A (en) AGENTS FOR PREVENTING AND TREATING PERIODONTOPATHIES
DE69812784D1 (en) Composition for the prevention and elimination of plant diseases
DE69840752D1 (en) USE OF COUMARINE FOR THE TREATMENT OF LIVER DISEASES AND PANCREAS DISEASES
DE69405919D1 (en) Compositions for the treatment of keratin fibers
ATE221763T1 (en) THE USE OF GLYCERYLTRIACETATE FOR THE TREATMENT OF ONYCHOMYCOSIS
DE59707519D1 (en) USE OF 1-HYDROXY-2-PYRIDONES FOR TREATING SKIN INFECTIONS
DE69841550D1 (en) TREATMENT OF FIBROMYALGIA AND RELATED DISEASES
DE69825319D1 (en) PREPARATION FOR THE PREVENTION AND TREATMENT OF INFLAMMATION
DE60027429D1 (en) DIHYDROBENZODIAZEPINES AND THEIR USE FOR THE TREATMENT OF DYSLIPIDIA
DE69913380D1 (en) COMPOSITION FOR THE TREATMENT OF PERIODONTAL DISEASES
DE69519040D1 (en) COMPOSITION FOR HYGIENE, PROPHYLAXIS AND TREATMENT OF THE MOUTH

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee